After the publication of the Drug Profile by Andrew Menzies-Gow and Kian Fan Chung, ‘Omalizumab for the treatment of severe allergic asthma’, published in the September 2008 issue of Expert Review of Clinical Immunology (Expert Rev. Clin. Immunol. 4[5], 543–548 [2008]), it has been brought to our attention that the Financial & competing interests disclosure was incorrectly printed as:
Financial & competing interests disclosure
KF Chung has participated in clinical trials of omalizumab, been renumerated for participation at Advisory board meetings for Novartis, and received educational grants for attending respiratory conferences from Novartis. He has also been renumerated for participation at Advisory Board meetings for GSK, Trinity-Chiesi, Gilead and Merck to discuss treatment for asthma and COPD. A Menzies-Gow has received fees from Novartis as a paid member of an advisory board and for providing educational lectures. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No external writing assistance was utilized in the production of this manuscript.
The correct Financial & competing interests disclosure is printed below:
Financial & competing interests disclosure
KF Chung has taken part in clinical trials of Omalizumab funded by Novartis Pharmaceuticals and has been a paid member of an Advisory Board on Omalizumab for Novartis (2004–2007). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No external writing assistance was utilized in the production of this manuscript.
The editors of Expert Review of Clinical Immunology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.